A Phase 1b, Open-label, Multicenter Study of (BMS-936564) in Combination With Lenalidomide (Revlimid) Plus Low-dose Dexamethasone, or With Bortezomib (Velcade) Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 18 Mar 2016
At a glance
- Drugs Ulocuplumab (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 15 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 10 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov.
- 10 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov.